UK’s NICE Recommends Amgen’s Kyprolis Triple Combo for Multiple Myeloma

The UK’s National Institute for Health and Care Excellence (NICE) says it recommends Amgen’s Kyprolis (carfilzomib) along with lenalidomide and dexamethasone for patients with multiple myeloma who have had at least one previous therapy.

According to NICE’s final guidance, the triple-combination treatment was demonstrated to extend remission and improve overall survival vs. lenalidomide and dexamethasone by themselves, with evidence suggesting the triple combination has benefits for up to six years.

Previous lines of therapy can include Johnson & Johnson subsidiary Janssen’s Velcade (bortezomib) targeted for multiple myeloma, NICE said.